genedrive
plc
("genedrive" or the
"Company")
Director/PDMR
Notification
genedrive plc (AIM: GDR), the point
of care pharmacogenetic testing company announces that on 20
December 2024, Dr Ian Gilham, Non-Executive Chairman, acquired
225,000 ordinary shares of 1.5p each ("Ordinary Shares") at 2.344p
per share, Dr Gino Miele, Chief Executive Officer, acquired
1,135,208 Ordinary Shares in the Company at a price of 2.2p per
share, Russ Shaw, Chief Financial Officer, acquired 1,000,000
Ordinary Shares in the Company at a price of 2.189p per share,
Patrick Breen, Chief Commercial Officer and a PDMR, acquired
509,136 Ordinary Shares in the Company at a price of 2.195p per
share and Tom Lindsay, Non-Executive Director, acquired 222,222
Ordinary Shares in the Company at a price of 2.25p per
share.
Following these purchases, Dr Ian
Gilham, is interested in 2,505,961 Ordinary Shares, 0.46% of the
issued share capital of the Company, Dr Gino Miele, is interested
in 2,202,187 Ordinary Shares, 0.41% of the issued share capital of
the Company, Russ Shaw is interested in 2,700,000 Ordinary Shares,
0.50% of the issued share capital of the Company, Patrick Breen is
interested in 509,136 Ordinary Shares, 0.09% of the issued
share capital of the Company and Tom Lindsay is interested in
1,151,605 Ordinary Shares, 0.21% of the issued share capital of the
Company.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a.
|
Name
|
1. Dr Ian
Gilham
2. Dr Gino
Miele
3. Russ
Shaw
4. Patrick
Breen
5. Tom
Lindsay
|
2.
|
Reason for the notification
|
a.
|
Position/status
|
1. Non-Executive
Chairman
2. Chief Executive
Officer
3. Chief Financial
Officer
4. Chief
Commercial Officer
5. Non-Executive
Director
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
genedrive plc
|
b.
|
LEI
|
213800ZYODIRZ87Y4K14
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the
Financial instrument,
type
of instrument
Identification code
|
Ordinary Shares of 1.5p
each
GB00B1VKB244
|
b.
|
Nature of the transaction
|
Purchase of ordinary
shares
|
c.
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
1.
2.344p
2.
2.200p
3.
2.189p
4.
2.195p
5.
2.250p
|
225,000
1,135,208
1,000,000
509,136
222,222
|
|
d.
|
Aggregated information
· Aggregated volume
· Price
|
1.
£5,274.00
2.
£24,974.58
3.
£21,890.00
4.
£11,175.54
5.
£5,000.00
|
e.
|
Date of the transaction
|
20 December 2024
|
f.
|
Place of the transaction
|
London Stock Exchange, AIM Market
(XLON)
|
For further details please
contact:
genedrive plc
|
+44 (0)161
989 0245
|
Gino Miele: CEO / Russ Shaw:
CFO
|
|
|
|
Peel
Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
James Steel / Patrick
Birkholm
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About genedrive plc
(http://www.genedriveplc.com). genedrive plc is a pharmacogenetic
testing company developing and commercialising a low cost, rapid,
versatile and simple to use point of need pharmacogenetic platform
for the diagnosis of genetic variants. This helps clinicians to
quickly access key genetic information that will aid them make the
right choices over the right medicine or dosage to use for an
effective treatment, particularly important in time-critical
emergency care healthcare paradigms. Based in the UK, the Company
is at the forefront of Point of Care pharmacogenetic testing in
emergency healthcare. Pharmacogenetics informs on how your
individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be
personalised, made safer and more effective. The Company has
launched its two flagship products, the Genedrive® MT-RNR1 ID Kit
and the Genedrive® CYP2C19 ID Kit, both developed and validated in
collaboration with NHS partners and deployed on its point of care
thermocycler platform. Both tests are single-use disposable
cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the
Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians
to make a decision on antibiotic use in neonatal intensive care
units within 26 minutes, ensuring vital care is delivered, avoiding
adverse effects potentially otherwise encountered and with no
negative impact on the patient care pathway. Its CYP2C19 ID Kit
which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke
patients in 70 minutes, ensuring that patients who are unlikely to
benefit from or suffer adverse effects from Clopidogrel receive an
alternative antiplatelet therapeutic in a timely manner, ultimately
improving outcomes. Both tests have undergone review by the
National Institute for Health and Care Clinical Excellence ("NICE")
and have been recommended for use in the UK NHS. The Company
has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio
expansion and strategic M&A, and operates out of its facilities
in Manchester.
The Company has a clear commercial
strategy focused on accelerating growth through maximising
in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in
Manchester.